Abstract
Results are presented from 186 hospitalized patients treated for acute purulent exacerbations of chronic bronchitis with orally administered ciprofloxacin (80 patients), enoxacin (26 patients), ofloxacin (30 patients) or pefloxacin (50 patients). In general, good clinical results were observed in 50–70% of the patients treated, most failures being due to relapses or reinfections withStreptococcus pneumoniae orPseudomonas aeruginosa. Studies on blood and sputum concentration suggested that gastro-intestinal absorption was not always satisfactory. Unwanted drug effects were noted with all agents studied, generally presenting as stomach pain, nausea, hallucinations, or dizziness. Most adverse drug reactions were seen with enoxacin, often but not always during concomitant treatment with theophylline.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Davies BI, Maesen FPV. The diagnosis and treatment of respiratory infections. In: Brumfitt W, Hamilton-Miller JMT, eds. A clinical approach to progress in infectious diseases. Oxford: Oxford University Press, 1983:132–58.
Bauernfeind A, Petermüller C.In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. Eur J Clin Microbiol 1983;2:111–5.
Muytjens H, Van der Ros-van de Repe J, Van Veldhuizen G. Comparative activities of ciprofloxacin (Bay 09867), norfloxacin, pipemidic acid, and nalidixic acid. Antimicrob Agents Chemother 1983;24:302–4.
Barry AL, Jones RN. Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin and oxolinic acid afterin vitro selection of resistant populations. Antimicrob Agents Chemother 1984;25:775–7.
Wise R. The activity of quinolones against respiratory tract pathogenes. Quinolones Bull June 1985;1:1–2.
Davies BI, Maesen FPV, Teengs JP. Serum and sputum concentrations of enoxacin after single oral dosing in a clinical and bacteriological study. J Antimicrob Chemother 1984;14(suppl 0):83–9.
Maesen FPV, Davies BI, Teengs JP. Pefloxacin in acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1985;16:379–88.
Davies BI, Maesen FPV, Baur C, Teengs JP, Cremer HMHG. Ciprofloxacin in purulent exacerbations of chronic bronchitis: a clinical microbiological and pharmacokinetic study. 14th International Congress of Chemotherapy. Kyoto. June 23–28. 1985. Kyoto: International Society of Chemotherapy, 1985:abstract S 50-3.
Mulder J, Goslings WRO, Van der Plas MC, Lopez Cardozo P. Studies on the treatment with antibacterial drugs of acute and chronic bronchitis caused byHaemophilus influenzae. Acta Med Scand 1952;143:32–49.
Davies BI, Maesen FPV; Brouwers J. Cefoperazone in acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1982;9:149–55.
Davies BI, Maesen FPV. Serum and sputum antibiotic levels after ampicillin. amoxycillin and bacampicillin in chronic bronchitis patients. Infection 1979;7(suppl 5):S465–8.
Davies BI, Maesen FPV, Brombacher PJ, Sjövall J. Twice daily dosage of bacampicillin in chronic bronchitis: a double blind study. Scand J Respir Dis 1978;59:249–56.
Wijnands WJA, Van Herwaarden CLA, Vree TB. Enoxacin raises plasma theophylline concentrations. Lancet 1984;2:108.
Maesen FPV, Teengs JP, Baur C, Davies BI. Quinolones and raised plasma concentrations of theophylline. Lancet 1984;2:530.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Davies, B.I., Maesen, F.P.V., Teengs, J.P. et al. The quinolones in chronic bronchitis. Pharmaceutisch Weekblad Scientific Edition 8, 53–59 (1986). https://doi.org/10.1007/BF01975481
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01975481